Targeting KIT by frameshifting mRNA transcripts as a therapeutic strategy for aggressive mast cell neoplasm
A treatment to prevent extreme symptoms and cut hospitalisation
Formulation business grew by 15 per cent in the quarter
This robust performance is a testimony of the company's agility, resilience and strong execution capabilities during these difficult times
Purchase price of US $ 1.5 billion upfront and up to USD 500 million in success-based milestone payments
Deal signed with AOP Orphan for US commercial rights
It leverages Kite’s Chimeric Antigen Receptors and Appia Bio’s Allogeneic Cell Technology Platform to Develop Off-the-Shelf Cell Therapies
The product can be used by any lab that conducts NGS testing, making precision medicine accessible to all cancer patients
Founded in 2019, the start-up develops digital therapeutics, a therapeutic intervention from the convergence of biology and information technology
He will be responsible for the company's overall strategy and provide the necessary direction and dynamic leadership to R&D, manufacturing, business development, and commercial operations
Subscribe To Our Newsletter & Stay Updated
